Source: International Congress 2016 – Pulmonary drug delivery
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Annalisa Piccinno (Parma, Italy), Annalisa Piccinno, Lisa D’Amato, Mario Scuri, Annamaria Muraro, Daniela Acerbi. Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI. Eur Respir J 2016; 48: Suppl. 60, 962

Member's Comments

No comment yet.

Related content which might interest you: Effect of antistatic AeroChamber Plus® Flow-Vu® spacer on the systemic bioavailability of CHF5993 a novel triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Bronchodilator effect of high strength extrafine BDP/formoterol delivered via NEXThaler® in asthmatics Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Safety profile and pharmacokinetics of an inhaled GATA-3-specific DNAzyme in a phase Ib study in patients with stable allergic asthma Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003 Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014 In vitro validation of the use of a spacer with an extrafine beclomethasone/formoterol formulation Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 Biopharmaceutical and chemical compatibility of the combination of salbutamol hemisuccinate and methatropium iodide Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 In vitro profile of the new inhaled pan-JAK inhibitor LAS194046 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Effect of inhaled beclomethasone or placebo on brain stem activity in a patient chronically treated with steroids - Preliminary report Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 In vitro characterization of a novel inhaled PI3Kd inhibitor LAS194223 Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014